Objective
Despite of their great promise, high-throughput technologies in cancer research have often failed to translate to major therapeutic advances in the clinic. One challenge has been tumour heterogeneity, where multiple competing subclones coexist within a single tumour. Genomic heterogeneity renders it difficult to identify all driving molecular alterations, and thus results in therapies that only target subsets of aggressive tumour cells. Another challenge lies in the integration of multiple types of molecular data into mathematical disease models that can make actionable clinical statements.
We aim to develop predictive computational technology that can exploit molecular and clinical data to improve our understanding of disease mechanisms and to inform clinicians about optimized strategies for therapeutic intervention. We propose to focus on prostate cancer, a leading cause of cancer death amongst men in Europe, but also prone to over-treatment. Our approach combines the exploitation of genomic, transcriptomic, proteomic, and clinical data in primary and metastatic tumours, prospective cohorts of well characterized prostate cancer patients, drug screenings in cell lines, and the use of the Watson technology, a last generation cognitive computer developed at IBM.
The translational objective of this study is to develop technology for identifying disease mechanisms and produce treatment recommendations for individual patients based on a therapeutic biomarker panel. The proposed software framework will be accessible through a graphical interface that will facilitate its dissemination and use by researchers, clinicians, and biomedical industries. The framework will provide intuitive tools to deposit, share, analyze, and visualize molecular and clinical data; as well as to infer prognosis, elucidate implicated mechanisms and recommend therapy accordingly. This software framework will serve as a proof of concept for future development by industrial partners in Europe.
Fields of science
- medical and health sciencesclinical medicineoncologyprostate cancer
- natural sciencescomputer and information sciencessoftware
- medical and health sciencesclinical medicineallergologydrug allergy
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistance
- natural sciencescomputer and information sciencesartificial intelligencecomputational intelligence
Programme(s)
Funding Scheme
RIA - Research and Innovation action
Coordinator
9500 Villach
Austria
See on map
Participants (9)
8803 Rueschlikon
See on map
64289 Darmstadt
See on map
52074 Aachen
See on map
8092 Zuerich
See on map
8006 Zurich
See on map
77030 Houston Tx
See on map
75231 Paris
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
75654 Paris
See on map
6726 Szeged
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.